Abstract:RANKL/RANK/OPG system consists of three essential signaling molecules: i) the receptor activator of nuclear factor (NF)-kB-ligand (RANKL), ii) the receptor activator of NF-kB (RANK), and iii) the soluble decoy receptor osteoprotegerin (OPG). Although this system is critical for the regulation of osteoclast differentiation/activation and calcium release from the skeleton, different studies have elucidated its specific role in mammary gland physiology and hormone-driven epithelial proliferation during pregnancy. Of note, several data suggest that progesterone induces mammary RANKL expression in mice and humans. In turn, RANKL controls cell proliferation in breast epithelium under physiological conditions typically associated with higher serum progesterone levels, such as luteal phase of the menstrual cycle and pregnancy. Hence, RANKL/RANK system can be regarded as a major downstream mediator of progesterone-driven mammary epithelial cells proliferation, potentially contributing to breast cancer initiation and progression. Expression of RANKL, RANK, and OPG has been detected in breast cancer cell lines and in human primary breast cancers. To date, dysregulation of RANKL/RANK/OPG system at the skeletal level has been widely documented in the context of metastatic bone disease. In fact, RANKL inhibition through the RANKL-blocking human monoclonal antibody denosumab represents a well-established therapeutic option to prevent skeletal-related events in metastatic bone disease and adjuvant therapy-induced bone loss in breast cancer. On the other hand, the exact role of OPG in breast tumorigenesis is still unclear. This review focuses on molecular mechanisms linking RANKL/RANK/OPG system to mammary tumorigenesis, highlighting pre-clinical and clinical evidence for the potential efficacy of RANKL inhibition as a prevention strategy and adjuvant therapy in breast cancer settings.

Receptor Activator Of Nuclear Factor-Kappa B Ligand (Rankl)/Rank/Osteoprotegerin System In Bone And Other Tissues

Receptor Activator of Nuclear Factor-Κb Ligand (rankl)/rank/osteoprotegerin System in Bone and Other Tissues (Review)

Role of OPG/RANKL/RANK system during alveolar bone resorption and remodeling

RANKL biology: bone metabolism, the immune system, and beyond

Discovery of the RANKL/RANK/OPG system

RANKL-independent modulation of osteoclastogenesis

Regulation of T cell-associated tissues and T cell activation by RANKL-RANK-OPG

Tumor Necrosis Factor Receptor Family Member Rank Mediates Osteoclast Differentiation And Activation Induced By Osteoprotegerin Ligand

TNF-family member Receptor Activator of NF-κB (RANK) and RANK-Ligand (RANKL) in bone remodelling

Structural and Functional Insights of RANKL-RANK Interaction and Signaling.

RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives

Correlating Rank Ligand/Rank Binding Kinetics with Osteoclast Formation and Function

Roles of osteoprotegerin in endocrine and metabolic disorders through receptor activator of nuclear factor kappa-B ligand/receptor activator of nuclear factor kappa-B signaling

Roles of the RANKL–RANK Axis in Immunity—Implications for Pathogenesis and Treatment of Bone Metastasis

Application of osteoprotegerin in periodontal tissue regeneration

The Role of RANKL in Bone Remodeling

Research Progress of RANK/RANKL/OPG Signaling Pathway

RANKL and OPG Regulation on Bone Remodeling

The RANK/RANKL/OPG system and tumor bone metastasis: Potential mechanisms and therapeutic strategies

[Osteoclast Differentiation Regulated by Receptor Activator of Nuclear Factor Kappab Probably Through a Novel Signaling Pathway].

Expression Profile of Receptor Activator of Nuclear-Κb (RANK), RANK Ligand (RANKL) and Osteoprotegerin (OPG) in Breast Cancer.